Updates to our Terms of Use

We are updating our Terms of Use. Please carefully review the updated Terms before proceeding to our website.

Thursday, April 18, 2024 | Back issues
Courthouse News Service Courthouse News Service

Shareholder Derivative

NASHVILLE - Directors of Provectus Biopharmaceuticals misrepresented the status of its primary product, a melanoma drug, and the share price fell from $5.22 to 73 cents after the truth came out, shareholders claim in a federal derivative complaint.

Categories / Uncategorized

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Loading...